Actinogen Medical Ltd (ASX: ACW) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Actinogen Limited. Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $165.57 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.66 billion
Earnings per share -0.003
Dividend per share N/A
Year To Date Return 376.19%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Actinogen Medical Ltd (ASX: ACW)
Latest News

ACW ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Actinogen Medical Ltd

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

ACW Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 Sep 2021 $0.10 $0.01 11.11% 4,495,033 $0.09 $0.11 $0.09
16 Sep 2021 $0.09 $0.00 0.00% 511,627 $0.09 $0.09 $0.09
15 Sep 2021 $0.09 $0.00 0.00% 1,473,064 $0.09 $0.09 $0.09
14 Sep 2021 $0.09 $0.00 0.00% 2,373,289 $0.09 $0.10 $0.09
13 Sep 2021 $0.09 $0.00 0.00% 1,625,139 $0.09 $0.10 $0.09
10 Sep 2021 $0.09 $0.00 0.00% 2,232,713 $0.09 $0.10 $0.09
09 Sep 2021 $0.09 $-0.01 -10.00% 6,721,382 $0.10 $0.10 $0.09
08 Sep 2021 $0.10 $0.00 0.00% 1,541,449 $0.11 $0.11 $0.10
07 Sep 2021 $0.11 $-0.01 -9.09% 8,598,798 $0.11 $0.12 $0.10
06 Sep 2021 $0.11 $0.00 0.00% 1,600,896 $0.11 $0.11 $0.11
03 Sep 2021 $0.11 $0.01 9.52% 3,800,353 $0.11 $0.11 $0.11
02 Sep 2021 $0.11 $0.00 0.00% 1,281,261 $0.11 $0.11 $0.11
01 Sep 2021 $0.11 $-0.01 -9.09% 1,686,221 $0.11 $0.11 $0.11
31 Aug 2021 $0.11 $0.02 21.28% 4,064,417 $0.10 $0.11 $0.10
30 Aug 2021 $0.09 $0.00 0.00% 1,981,694 $0.10 $0.10 $0.09
27 Aug 2021 $0.09 $-0.01 -10.00% 3,838,939 $0.10 $0.11 $0.09
26 Aug 2021 $0.10 $0.00 0.00% 4,692,410 $0.11 $0.11 $0.10
25 Aug 2021 $0.11 $0.01 10.87% 9,252,685 $0.09 $0.11 $0.09
24 Aug 2021 $0.09 $0.01 12.82% 9,926,660 $0.08 $0.09 $0.08
23 Aug 2021 $0.08 $0.00 0.00% 3,422,486 $0.08 $0.08 $0.08

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
17 Nov 2020 George Morstyn Issued 40 $880
Rights issue.
17 Nov 2020 Malcolm McComas Issued 100 $2,200
Rights issue.
17 Nov 2020 Geoffrey Brooke Issued 265 $5,830
Rights issue.
17 Nov 2020 John (Bill) Ketelbey Issued 128 $2,828
Rights issue. As per announcement on 17/11/2020.
17 Nov 2020 John (Bill) Ketelbey Issued 1 $40,968
Rights issue.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr George Morstyn Non-Executive Director Dec 2017
Dr Morstyn has more than 25 years; experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc. Dr Morstyn had responsibility globally for drug development in all therapeutic areas including neuroscience at Amgen Inc. and was a member of the Operating Committee. Many new products were approved and launched during Dr Morstyn's tenure. Prior to joining Amgen Inc. Dr Morstyn has been a Non-Executive Director of various for-profit and not-for-profit companies, including many biotechnology companies. He is currently on the Board of the Cooperative Research Centre for Cancer Therapeutics, Symbio (Tokyo) and Biomedical Research Victoria.
Mr Malcolm John McComas Non-Executive Director Apr 2019
Mr McComas has over 25 years of experience in the financial services industry with experience in corporate finance, mergers and acquisitions, debt and equity funding transactions across multiple industry sectors. He held senior leadership roles with Grant Samuel, County NatWest (now Citigroup) and Morgan Grenfell (now Deutsche Bank) in Australia and the UK. Prior to this Mr McComas was a lawyer at Herbert Geer specialising in tax. Mr McComas is an experienced company director and currently services number of listed entities, and also has not-for-profit involvement as a director of the Australasian Leukemia and Lymphoma Group.
Dr Geoffrey E.D Brooke Non-Executive ChairmanNon-Executive Director Feb 2021
Dr Brooke is a healthcare industry and venture capital veteran with over 30 years' international experience as the founder, lead investor and/or Chairman/Director of numerous healthcare companies. He was the Managing Director and Founder of leading life sciences venture capital firm, GBS Ventures. There, Dr Brooke was responsible for GBS's healthcare venture activity in the region. Dr Brooke was also responsible for numerous investments and exits via NASDAQ and ASX public listings and trade sales, as well as being lead investor in numerous investments syndicated in multiple rounds with premier US venture firms. Dr Brooke was also President and Founder of US-based seed healthcare venture capital firm, Medvest Inc., with investors including the venture capital arm of global multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, Johnson & Johnson. Dr Brooke now acts as a private investor in, and independent director for, a number of small to medium-sized Australian and US private and public companies.
Dr Steven Gourlay Chief Executive OfficerManaging Director Mar 2021
Dr Gourlay has more than 30 years of experience in the development of novel therapeutics. Formerly the founding Chief Medical Officer (CMO) at US-based Principia Biopharma Inc., Dr Gourlay was responsible for the supervision of multiple pre-clinical, first-in-human, Phase 2 and 3 clinical trial programs for four small molecules in orphan immunological diseases, multiple sclerosis and cancer. The data generated by these trials, and Dr Gourlay's roadshow presentations, supported a NASDAQ IPO of Principia Biopharma Inc. in 2018 - subsequently followed by an acquisition of by Sanofi in 2020. Prior to Principia Biopharma, Dr Gourlay was a Partner at GBS Venture Partners, the Australian specialist life sciences and healthcare venture capital firm, where he was involved in the development and exit of multiple clinical stage therapeutic companies including Elastagen, Spinifex and Peplin. Before GBS, and after a postdoc in clinical pharmacology at the University of California San Francisco, he held positions of increasing responsibility at Genentech, Inc. in the areas of pharmacoepidemiology and early clinical development. Dr Gourlay has drug regulatory experience with the US Food and Drug Administration (FDA), European Medicines Agency (EMA) at many levels, including filing more than 10 Investigational New Drug (IND) applications, achieving several orphan drug status approvals for his Company's product(s), and completing several biologics license applications. Dr Gourlay has been acting as a consultant CMO to Actinogen since December 2020.
Mr Peter Webse Company Secretary
-
Peter Webse Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 227,303,623 20.36%
Edinburgh Technology Fund Limited 48,147,864 4.31%
Surfit Capital Pty Ltd 30,000,000 2.69%
Tisia Nominees Pty Ltd (Henderson Family A/C) 27,867,184 2.50%
Mrs Sarah Cameron 25,916,573 2.32%
Brazil Farming Pty Ltd 15,000,000 1.34%
Citicorp Nominees Pty Ltd 10,604,474 0.95%
Mr Steven Veronese 10,008,001 0.90%
Oaktone Nominees Pty Ltd (Grist Investment A/C) 10,000,000 0.90%
Mrs Gillian Karen Nes & Mrs Ronald Nes (Giro S/F A/C) 9,950,000 0.89%
Kaleidoscope Holdings Pty Ltd (Kaleidoscope Super A/C) 9,000,000 0.81%
Griffin & Grace Investments Pty Ltd (Griffin & Grace Inv S/F A/C) 8,800,000 0.79%
Mr Peter James Nixon 8,400,000 0.75%
Alua Capital Pty Ltd 8,000,000 0.72%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd Drp 7,738,901 0.69%
BNP Parabis Nominees Pty Ltd (Bnpp Nyb Clearing Acc Drp) 7,560,729 0.68%
Bannaby Investments Pty Ltd (Super Fund A/C) 7,500,000 0.67%
Webinvest Pty Ltd (Olsb Unit A/C) 7,000,000 0.63%
Romfal Sifat Pty Ltd (The Fizmail Family A/C) 7,000,000 0.63%
Paranji Super Fund Pty Ltd (Paranji Superfund A/C) 6,500,000 0.58%

Profile

since

Note